We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Bioorthogonal Palladium-Labile Prodrugs for Site-Specific Anticancer Therapy

Video   Apr 23, 2015


About the Speaker
Asier Unciti-Broceta is a group leader of the Edinburgh Cancer Research UK Centre (University of Edinburgh). His research group is interested in the interface of chemistry and biomedicine, particularly on the development of novel chemical approaches for anticancer drug discovery. He is a member of the RSE Young Academy of Scotland and serves as Associate Editor of Frontiers in Chemistry (Medicinal and Pharmaceutical Chemistry specialty) since 2013. Among his awards highlight being recipient of the Nexxus (East) Young Life Scientist Award of 2010 and the RSC Young Industrialist Award of 2012.Abstract
The goal of performing bio-independent syntheses in biological environs, so called bioorthogonal chemistry, has inspired the search for novel biocompatible organic reactions for more than a decade and found a niche application as a labelling strategy to study biomolecules in their native state . While metal-free bioorthogonal reactions are considered optimal for living systems due to their biocompatibility, significant progress has been made in recent years by our group and others in the development of cell-tolerated bioorthogonal organometallic (BOOM) reactions, opening up new avenues for the exploitation of the bioorthogonal paradigm. However, the potential of such selective processes in medicine is yet to be determined. Based on the biocompatibility of metallic palladium (widely used, e.g., in dental restoration and jewelry) and its remarkable catalytic properties, our group investigates the use of heterogeneous palladium catalysis to enable site-specific conversion of cytotoxic prodrugs into its active form. As opposed to biolabile prodrugs, whose activation process relies on metabolic pathways, an efficient Pd0-activated prodrug therapy would be entirely dependent on the distinct catalytic properties of this metal and therefore the prodrug would remain intact in the absence of a Pd0 source. In this talk I will present the discovery of two palladium-mediated deprotections that take place under biocompatible conditions and their application as masking methods to suppress the activity of chemotherapeutic drugs, while enabling the bioorthogonal rescue of the drugs’ pharmacological properties by heterogeneous palladium chemistry in cancer cell culture.


Recommended Videos

Cancer Clinical Trials: Trial Phases


Cancer clinical trials are done in trial phases; each trial phase is designed to answer a specific research question while providing clinical care.


Inactive Ingredients in Medication and Their Side Effects


This video discusses the question: What's in your medication?


Nanoscience and Drug Delivery – Small Particles for Big Problems


Getting sufficient therapeutic drugs to the precise disease cell would reduce the amount of medication required; reduce side effects; and enhance treatment. Taylor Mabe explores the use of nano-particles for this purpose.



To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free